Currently, targeting CD46 as a therapeutic strategy in cancers has attracted increasing attention to overcome the poor therapeutic efficacy of conventional cancer treatments, including the inhibition of CD46 expression (11, 29–31), neutralizing (blocking) mAbs (30–32), anti-CD46 antibody−drug conjugates (CD46-ADCs) (21, 33–36), and oncolytic virotherapy (37–42). Here, CD46 is linked to cancer.